Summit Global Investments Sells 3,327 Shares of United Therapeutics Corporation $UTHR

Summit Global Investments lowered its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 18.1% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 15,006 shares of the biotechnology company’s stock after selling 3,327 shares during the quarter. Summit Global Investments’ holdings in United Therapeutics were worth $6,291,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of UTHR. Wilmington Savings Fund Society FSB increased its position in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 49 shares during the period. Chung Wu Investment Group LLC bought a new stake in United Therapeutics in the 2nd quarter valued at about $29,000. WealthCollab LLC grew its position in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. increased its holdings in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the period. Finally, True Wealth Design LLC increased its holdings in shares of United Therapeutics by 738.5% during the third quarter. True Wealth Design LLC now owns 109 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 96 shares during the period. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Up 0.1%

United Therapeutics stock opened at $467.70 on Friday. The stock has a market cap of $20.14 billion, a PE ratio of 17.72, a P/E/G ratio of 2.50 and a beta of 0.84. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $519.99. The business’s 50-day moving average price is $487.37 and its two-hundred day moving average price is $418.94.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. The firm had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $6.39 earnings per share. As a group, analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction on Monday, January 26th. The shares were sold at an average price of $471.91, for a total transaction of $10,617,975.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of the company’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $469.89, for a total transaction of $3,900,087.00. Following the transaction, the executive vice president owned 36,781 shares of the company’s stock, valued at $17,283,024.09. This trade represents a 18.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 566,864 shares of company stock worth $269,514,607 over the last quarter. Corporate insiders own 10.30% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of analyst reports. Jefferies Financial Group reissued a “buy” rating and set a $575.00 price target on shares of United Therapeutics in a research report on Wednesday, November 19th. UBS Group upped their target price on United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Royal Bank Of Canada increased their target price on United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a report on Thursday, October 30th. HC Wainwright boosted their price target on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Finally, Wells Fargo & Company increased their price objective on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $509.50.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.